20 March 2019
A revolutionary treatment to tackle one of the major diseases affecting dairy herds has been unveiled by Dechra Veterinary Products.
Revozyn® RTU, which contains 400 mg/ml Penethamate hydriodide, is the first ready-to-use injectable narrow spectrum Penethamate on the UK market for cases of subclinical and clinical local mastitis. It can also be used to treat relapses of old infections.
Its new formulation features an ion trapping mechanism that results in high Benzylpenicillin concentration in milk and udder tissue. The intramuscular injection works by diffusing through the blood vessels and accumulating in the udder tissue and milk, treating the whole udder effectively.
Revozyn® RTU comes in a 50ml multi dose vial making it both convenient and cost effective. It has a 28-day shelf life after first use and has withdrawal periods of four days for milk and 10 days for meat and offal.
Dechra Brand Manager Emma Jennings said: “The treatment and control of mastitis is one of the largest costs to any dairy farmer. It affects productivity and cow welfare and we are delighted to be able to introduce this revolutionary product.
“Revozyn® RTU can change the way that clinical and subclinical mastitis in dairy cattle is treated. Its narrow spectrum of activity means that the risk of antibiotic resistance is reduced and there is no need for additional animal handling, thereby saving time and protecting user safety.
“The flexible dosing of Revozyn® RTU and 28-day shelf life also make it a cost effective option for farmers,” she added.
For more information, go to www.dechra.co.uk.
Breakthrough mastitis treatment for cows rolled out by Dechra